Somite Therapeutics
Redefining Cell Therapy with Artificial Intelligence
Redefining Cell Therapy with Artificial Intelligence
Somite.ai is a venture-backed company aiming to become the OpenAI of stem cell biology, developing AI foundation models to produce human tissue for cell therapies at scale for diseases such as diabetes, obesity, and muscular dystrophies. Somite's AI platform, AlphaStem, fuels a virtuous cycle: It enables new cell therapies, generating massive data that further improve the platform, empowering even faster therapy creation with broader applications. The company's pipeline includes the promising SMT-M01 program for Duchenne muscular dystrophy (DMD) and the SMT-B01 program for metabolic disorders. Incorporated in Oct. 2023, Somite.ai has raised over $10m to date.
There is no investment information
No recent news or press coverage available for Somite Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.